Sanofi’s Leading Role in Addressing Inflammatory Diseases Highlighted at AAAAI Conference The latest data presented at the American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting sheds light on Sanofi’s robust scientific leadership in managing inflammatory diseases. Among the…
Eli Lilly and Company (NYSE:LLY) has announced that Philip Johnson, the group vice president and treasurer, will be retiring from the company after more than 28 years of service. His retirement is scheduled for the end of February, as he…
Novartis has announced its intent to initiate a voluntary public takeover offer for the acquisition of MorphoSys AG (FSE: MOR; NASDAQ: MOR), a global biopharmaceutical company headquartered in Germany, specializing in innovative oncology medicines. The proposed acquisition, contingent upon customary…
Merck Animal Health, operating as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc. (NYSE: MRK), headquartered in Rahway, N.J., USA, has officially entered into a definitive agreement to acquire Elanco Animal Health…
Eli Lilly and Company (NYSE: LLY) disclosed its financial outcomes for the final quarter of 2023, marking a year of notable accomplishments characterized by substantial revenue growth. David A. Ricks, Lilly’s chair and CEO, emphasized the company’s impactful contributions in…
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).1,2 Whereas available RVO treatments are…
Grifols, a distinguished global healthcare company with a 115-year legacy as a leading manufacturer of plasma-derived medicines, has bolstered its senior management team through two strategic appointments. Dr. Roland Wandeler assumes the role of President for the Biopharma Business Unit,…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has reported positive outcomes from its Phase 3 program for VX-548, a selective NaV1.8 inhibitor, designed to address moderate-to-severe acute pain. The Phase 3 program encompassed two pivotal trials following abdominoplasty and bunionectomy surgery, as…
In Q4 2023, Sanofi experienced a robust sales growth of 9.3% at Constant Exchange Rates (CER) and an 8.2% increase in business EPS. Notable achievements include Specialty Care’s 13.7% growth fueled by the success of Dupixent and ALTUVIIIO launches, which…
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review by the US Food and Drug Administration (FDA) for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has disclosed compelling 72-week data derived from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in the treatment of macular edema stemming from branch and central retinal vein occlusion (BRVO and…
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has submitted a New Drug Application (NDA) for ultrahigh-dose mecobalamin (development code: E0302) for the indication of amyotrophic lateral sclerosis (ALS) to the Pharmaceuticals and Medical Devices…